secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longevity Health Holdings, Inc. (XAGE)
CIK:        0001842939
Form:       8-K
Filed at:   2025-07-14T23:59:59+00:00
Accession:  0000950170-25-095608
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 5.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longevity Health to merge with THPlasma in $59M all-stock deal; Biolabs terminated
--------------------------------------------------------------------------------

- Merger values THPlasma at $59M plus $20M earnout; Longevity shares at $3.00 (12% premium to July 11 close).
- THPlasma has 5 plasma centers; FY2025E revenue $10M, EBITDA $2M; FY2026E revenue $32M, EBITDA $7M.
- Post-closing (Q4 2025), Rajiv Shukla becomes Executive Chairman; George Chi becomes Co-Chairman & CEO.
- Prior merger with 20/20 Biolabs automatically terminated July 8, 2025; no termination fees.
- No cash condition precedent; approved by both boards, subject to stockholder and Nasdaq approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842939/000095017025095608/0000950170-25-095608-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842939/000095017025095608/xage-20250708.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-095608

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer